- Home
- DNUT vs ZLAB Comparison
DNUT vs ZLAB Comparison
Compare DNUT & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNUT
- ZLAB
- Stock Information
- Founded
- DNUT 1937
- ZLAB 2013
- Country
- DNUT United States
- ZLAB China
- Employees
- DNUT N/A
- ZLAB N/A
- Industry
- DNUT Food Chains
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- DNUT Consumer Staples
- ZLAB Health Care
- Exchange
- DNUT Nasdaq
- ZLAB Nasdaq
- Market Cap
- DNUT 1.9B
- ZLAB 1.8B
- IPO Year
- DNUT 2021
- ZLAB 2017
- Fundamental
- Price
- DNUT $11.35
- ZLAB $31.24
- Analyst Decision
- DNUT Buy
- ZLAB Strong Buy
- Analyst Count
- DNUT 9
- ZLAB 4
- Target Price
- DNUT $15.56
- ZLAB $52.50
- AVG Volume (30 Days)
- DNUT 1.1M
- ZLAB 976.3K
- Earning Date
- DNUT 11-07-2024
- ZLAB 11-12-2024
- Dividend Yield
- DNUT 1.22%
- ZLAB N/A
- EPS Growth
- DNUT N/A
- ZLAB N/A
- EPS
- DNUT N/A
- ZLAB N/A
- Revenue
- DNUT $1,739,779,000.00
- ZLAB $322,711,000.00
- Revenue This Year
- DNUT $2.13
- ZLAB $48.34
- Revenue Next Year
- DNUT $7.84
- ZLAB $47.12
- P/E Ratio
- DNUT N/A
- ZLAB N/A
- Revenue Growth
- DNUT 8.06
- ZLAB 28.16
- 52 Week Low
- DNUT $9.18
- ZLAB $13.48
- 52 Week High
- DNUT $17.84
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- DNUT 56.23
- ZLAB 70.41
- Support Level
- DNUT $11.46
- ZLAB $31.52
- Resistance Level
- DNUT $11.82
- ZLAB $36.60
- Average True Range (ATR)
- DNUT 0.29
- ZLAB 1.36
- MACD
- DNUT 0.04
- ZLAB 0.34
- Stochastic Oscillator
- DNUT 81.12
- ZLAB 58.60
About DNUT Krispy Kreme Inc.
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S., includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line; International includes operations in the U.K., Ireland, Australia, New Zealand, and Mexico; and Market Development includes franchise operations across the globe, as well as operations in Japan. It derives maximum revenue from U.S. Segment.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.